Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Coverage · Pharmacy · Ophthalmology, PharmacyMedium impact

MA08.013, Revakinagene taroretcel-lwey (Encelto®)

Act
by Dec 29, 2025
Effective date
Dec 29, 2025
Identified
Oct 2, 2026

Summary

Independence Blue Cross Medicare Advantage has issued a new coverage policy for Encelto® (revakinagene taroretcel-lwey), an FDA-approved gene therapy for adults with idiopathic macular telangiectasia type 2 (MacTel). The policy establishes specific medical necessity criteria for coverage and identifies the applicable billing code (J3403). This is a brand-new policy effective immediately for MA plans with no prior guidance to supersede.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Dec 29, 2025 · 7 steps
01Billing and prior authorization teams must implement coverage criteria for Encelto® claims.
02Update billing system to recognize HCPCS code J3403 and flag for manual review or prior authorization.
03Establish prior authorization workflow requiring documentation of: diagnosis via fluorescein angiography/OCT/OCT angiography; BCVA of 54-letter ETDRS or 20/80 Snellen or better; absence of contraindications (infections, hypersensitivity to Endo-SFM, glaucoma, severe diabetic retinopathy, uveitis, intraretinal hyperreflectivity, neovascularization); no prior vitrectomy, keratoplasty, trabeculectomy, trabeculoplasty, recent lens removal, or recent YAG laser; ability to discontinue antithrombotic medication; and no prior Encelto® implant in the same eye.
04Train providers and clinical staff on MacTel diagnostic criteria and treatment eligibility.
05Update encounter forms/templates to capture required clinical documentation.
06Claims submitted without prior authorization or failing to meet all criteria will be denied.
07This applies only to Independence Blue Cross Medicare Advantage members.

Codes mentioned

J3403

Original notice

MA08.013, Revakinagene taroretcel-lwey (Encelto®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
08.02.44, Revakinagene taroretcel-lwey (Encelto®)MediumEffective Dec 29, 2025 · PharmacyMA08.013, Revakinagene taroretcel-lwey (Encelto®)LowEffective Dec 29, 2025 · Pharmacy08.02.44, Revakinagene taroretcel-lwey (Encelto®)MediumEffective Dec 29, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOphthalmologyPharmacyCode J3403

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account